Moody’s cuts Dave & Buster’s outlook to negative on sales slump

By Sep 28, 2026

Moody's — Moody’s cuts Dave & Buster’s outlook to negative on sales slump Investing.com

Auto-published by the finit.news Events monitor from Moody's; summarized by AI and may contain errors — verify against the primary source. September 28, 2026.

By

Credit Ratings

Governor Lamont and Treasurer Russell Applaud Announcement From S&P Global Ratings Improving Connecticut’s Credit Rating Outlook To Positive

Sep 28, 2026

Credit Ratings

Fitch cuts Pos Indonesia rating again after default

Sep 28, 2026

Credit Ratings

Fitch Raises Bulgaria Outlook to Positive, Keeps BBB+ Rating

Sep 28, 2026

Labor

Oregon’s public universities, classified workers narrowly avoid strike – Oregon Public Broadcasting

Regulatory Approvals

FDA Approves Zilurgisertib, an Oral ALK2 Inhibitor, for FOP

Regulatory Approvals

Roundup: FDA Approves Lilly’s Olumiant, AbbVie’s Juvmo, Mirum & Incyte’s Atebrioz

Regulatory Approvals

Moody’s cuts Dave & Buster’s outlook to negative on sales slump

By

Financial News For All

Oregon’s public universities, classified workers narrowly avoid strike – Oregon Public Broadcasting

FDA Approves Zilurgisertib, an Oral ALK2 Inhibitor, for FOP

Roundup: FDA Approves Lilly’s Olumiant, AbbVie’s Juvmo, Mirum & Incyte’s Atebrioz

FDA Approves AbbVie’s Juvmo for Parkinson Disease

Moody’s cuts Dave & Buster’s outlook to negative on sales slump

By

Related Post

Governor Lamont and Treasurer Russell Applaud Announcement From S&P Global Ratings Improving Connecticut’s Credit Rating Outlook To Positive

Fitch cuts Pos Indonesia rating again after default

Fitch Raises Bulgaria Outlook to Positive, Keeps BBB+ Rating

Financial News For All

Oregon’s public universities, classified workers narrowly avoid strike – Oregon Public Broadcasting

FDA Approves Zilurgisertib, an Oral ALK2 Inhibitor, for FOP

Roundup: FDA Approves Lilly’s Olumiant, AbbVie’s Juvmo, Mirum & Incyte’s Atebrioz

FDA Approves AbbVie’s Juvmo for Parkinson Disease